Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.
In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.
The moves are part of an organizational restructuring designed to increase the company's focus on its core women's health business and reduce operating costs.
A private financing fell short of its goal and the IDL joint venture has been unable to its obligations to GeneNews and Cobalt Healthcare, the owners of the JV.
NEW YORK (GenomeWeb) – During its fiscal third quarter, Thermo Fisher Scientific took $12.8 million in charges related to severance, the company disclosed in its Form 10-Q filed recently with the US Securities and Exchange Commission.
NEW YORK (GenomeWeb) – Australian molecular diagnostic firm Genetic Technologies today announced a restructuring aimed at ramping up its US molecular diagnostic operations and commercializing the new version of its BrevaGen breast cancer risk test.